Ameriprise’s ARK Genomic Revolution ETF ARKG Stock Holding History

Ameriprise’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,030	Closed	-$211K	–	3905
2023 Q1	$211K	Buy	+7,030	New	+$218K	﹤0.01%	3716

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Ameriprise's ARKG Position: Q2 2023 in Review

Ameriprise sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2023, closing a stake of 7,030 shares — an estimated $211K sold.

Ameriprise first reported a position in ARKG in Q1 2023 and held it in 1 quarter. The position peaked at $211K in Q1 2023. 290 funds tracked by Wall St. Rank hold ARKG as of Q2 2023.

Ameriprise reported no remaining ARK Genomic Revolution ETF position as of Q2 2023 after selling out during the quarter.
Ameriprise sold 7,030 ARK Genomic Revolution ETF shares in Q2 2023, an estimated $211K.
Ameriprise first reported a position in ARK Genomic Revolution ETF in Q1 2023 and held it in 1 quarter.
Ameriprise's ARK Genomic Revolution ETF position peaked at $211K in Q1 2023.
290 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2023.

Based on Ameriprise's 13F filing for Q2 2023, filed 14 Aug 2023.